MA32419B1 - Materiaux et procedes permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associees - Google Patents
Materiaux et procedes permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associeesInfo
- Publication number
- MA32419B1 MA32419B1 MA33461A MA33461A MA32419B1 MA 32419 B1 MA32419 B1 MA 32419B1 MA 33461 A MA33461 A MA 33461A MA 33461 A MA33461 A MA 33461A MA 32419 B1 MA32419 B1 MA 32419B1
- Authority
- MA
- Morocco
- Prior art keywords
- neurofibroma
- cells
- plexiform
- nfi
- tumor
- Prior art date
Links
- 201000004404 Neurofibroma Diseases 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 208000004748 plexiform neurofibroma Diseases 0.000 abstract 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 2
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 abstract 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 abstract 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 abstract 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 abstract 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 abstract 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000016361 genetic disease Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 210000004602 germ cell Anatomy 0.000 abstract 1
- 210000004524 haematopoietic cell Anatomy 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 229960003685 imatinib mesylate Drugs 0.000 abstract 1
- -1 imatinib mesylate compound Chemical class 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 210000004116 schwann cell Anatomy 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des mutations d'une lignée germinale dans le gène suppresseur de tumeur nfi dans la neurofibromatose de type 1 de von recklinghausen (nfi), un trouble génétique courant du système nerveux qui se caractérise par le développement d'un neurofibrome plexiforme. L'utilisation du transfert adoptif de cellules hématopoïétiques, a permis que le caractère hétérozygosité de nfi des cellules provenant de la moelle osseuse dans le microenvironnement tumoral était suffisant pour permettre la progression du neurofibrome dans le contexte de la zygosité inexistante des cellules de schwann. De plus, l'atténuation génétique ou pharmacologique de la voie de signalisation du kit-c dans les cellules hématopoïétiques réduit considérablement le démarrage et la progression du neurofibrome. Ces études ont permis d'identifier les cellules hématopoïétiques haploinsuffisantes et le récepteur du kit-c en tant que cibles thérapeutiques pour prévenir des neurofibromes plexiformes et impliquer des mastocytes en tant que médiateurs critiques du déclenchement de la tumeur. L'administration de doses thérapeutiquement efficaces d'un inhibiteur de tyrosine kinase, tel que le composé imatinib mésylate à un patient qui le nécessite permet de traiter des tumeurs chez un patient humain présentant un neurofibrome plexiforme.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7618508P | 2008-06-27 | 2008-06-27 | |
| US10365008P | 2008-10-08 | 2008-10-08 | |
| PCT/US2009/048554 WO2009158447A2 (fr) | 2008-06-27 | 2009-06-25 | Matériaux et procédés permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associées |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32419B1 true MA32419B1 (fr) | 2011-06-01 |
Family
ID=41445287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33461A MA32419B1 (fr) | 2008-06-27 | 2010-12-27 | Materiaux et procedes permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associees |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20110195975A1 (fr) |
| EP (1) | EP2291186A4 (fr) |
| JP (2) | JP2011526292A (fr) |
| KR (2) | KR20160011713A (fr) |
| CN (2) | CN102099038A (fr) |
| AU (1) | AU2009262214B9 (fr) |
| BR (1) | BRPI0914618A2 (fr) |
| CA (1) | CA2727737C (fr) |
| CL (1) | CL2009001486A1 (fr) |
| EA (2) | EA022611B1 (fr) |
| IL (1) | IL209973A (fr) |
| MA (1) | MA32419B1 (fr) |
| MX (1) | MX2010013918A (fr) |
| NZ (1) | NZ590076A (fr) |
| SG (1) | SG192444A1 (fr) |
| TW (1) | TWI508728B (fr) |
| WO (1) | WO2009158447A2 (fr) |
| ZA (1) | ZA201009066B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116574185A (zh) | 2012-07-25 | 2023-08-11 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
| CN113908269A (zh) * | 2014-05-23 | 2022-01-11 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
| KR101894769B1 (ko) | 2017-12-05 | 2018-09-04 | 아주대학교산학협력단 | siRNA를 포함하는 신경섬유육종 예방 또는 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| CA2439440A1 (fr) * | 2002-09-05 | 2004-03-05 | Emory University | Traitement de tumeurs associees a la sclerose tubereuse |
| ES2549327T3 (es) * | 2005-12-06 | 2015-10-27 | Novartis Ag | Derivados de pirimidilaminobenzamida para el tratamiento de la neurofibromatosis |
| WO2009100176A2 (fr) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase |
-
2009
- 2009-06-25 WO PCT/US2009/048554 patent/WO2009158447A2/fr not_active Ceased
- 2009-06-25 CA CA2727737A patent/CA2727737C/fr not_active Expired - Fee Related
- 2009-06-25 SG SG2013049952A patent/SG192444A1/en unknown
- 2009-06-25 EA EA201071340A patent/EA022611B1/ru not_active IP Right Cessation
- 2009-06-25 TW TW098121297A patent/TWI508728B/zh not_active IP Right Cessation
- 2009-06-25 US US12/996,891 patent/US20110195975A1/en not_active Abandoned
- 2009-06-25 EA EA201500525A patent/EA201500525A1/ru unknown
- 2009-06-25 EP EP09770980A patent/EP2291186A4/fr not_active Withdrawn
- 2009-06-25 KR KR1020167001722A patent/KR20160011713A/ko not_active Ceased
- 2009-06-25 KR KR1020107028646A patent/KR20110044945A/ko not_active Ceased
- 2009-06-25 BR BRPI0914618A patent/BRPI0914618A2/pt not_active IP Right Cessation
- 2009-06-25 CN CN2009801234742A patent/CN102099038A/zh active Pending
- 2009-06-25 CN CN201610089818.4A patent/CN105726542A/zh active Pending
- 2009-06-25 JP JP2011516634A patent/JP2011526292A/ja active Pending
- 2009-06-25 AU AU2009262214A patent/AU2009262214B9/en not_active Ceased
- 2009-06-25 MX MX2010013918A patent/MX2010013918A/es active IP Right Grant
- 2009-06-25 NZ NZ590076A patent/NZ590076A/xx not_active IP Right Cessation
- 2009-06-25 CL CL2009001486A patent/CL2009001486A1/es unknown
-
2010
- 2010-12-13 IL IL209973A patent/IL209973A/en not_active IP Right Cessation
- 2010-12-17 ZA ZA2010/09066A patent/ZA201009066B/en unknown
- 2010-12-27 MA MA33461A patent/MA32419B1/fr unknown
-
2013
- 2013-09-20 US US14/032,994 patent/US8933082B2/en not_active Expired - Fee Related
-
2014
- 2014-11-18 US US14/546,827 patent/US9345704B2/en not_active Expired - Fee Related
-
2015
- 2015-04-01 JP JP2015075280A patent/JP2015187104A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Simonetti et al. | Aneuploidy: Cancer strength or vulnerability? | |
| Li et al. | Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma | |
| Schmid et al. | EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases | |
| Zou et al. | Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer | |
| Kubo et al. | MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors | |
| MA42999B1 (fr) | Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë | |
| Malumbres et al. | Cell cycle kinases in cancer | |
| MA52288B1 (fr) | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci | |
| Hayakawa et al. | Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation | |
| Padul et al. | ETV/Pea3 family transcription factor‐encoding genes are overexpressed in CIC‐mutant oligodendrogliomas | |
| MA43000B1 (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| MA48772B1 (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA38175A1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
| Kaur et al. | Bromodomain and hedgehog pathway targets in small cell lung cancer | |
| MA30084B1 (fr) | Triazolopyridazines en tant que modulateurs de la tyrosine kinase | |
| MA31001B1 (fr) | Quinazolines destines a l'inhibition de pdk | |
| Suyama et al. | Expression of cancer/testis antigens in prostate cancer is associated with disease progression | |
| MA33658B1 (fr) | N-4(-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phényl)-4-(4-méthyl-2- thiényl)-1-phtalazinamine destinée à être utilisée dans le traitement d'un cancer résistant aux agents antimitotiques | |
| Lee et al. | ARID1B alterations identify aggressive tumors in neuroblastoma | |
| MA32419B1 (fr) | Materiaux et procedes permettant de supprimer et/ou de traiter un neurofibrome et des tumeurs associees | |
| Cseh et al. | PARP inhibitor PJ34 protects mitochondria and induces DNA-damage mediated apoptosis in combination with cisplatin or temozolomide in B16F10 melanoma cells | |
| Qin et al. | TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death | |
| MA50675B1 (fr) | Inhibiteurs de la creb binding protein (cbp) | |
| Sheng et al. | Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells | |
| Shakiba et al. | Investigating the expression and promoter methylation of RET gene in patients with medullary thyroid cancer with unmutated RET |